治疗后肿瘤灌注参数变化有助于预测高级别星形细胞瘤患者的生存
研究纳入45例组织学确诊的高级别星形细胞瘤患者(8例III级、37例IV级),于治疗前后行T2*加权对比增强MR灌注成像,计算肿瘤、瘤周及对照区CBF、CBV、MTT、Ktrans-T2*等参数的相对变化。结果显示肿瘤区CBV第90百分位升高或停滞与较短生存相关,下降与较长生存相关;Ktrans-T2*结果类似;瘤周区参数与总生存无关。
要点
- 肿瘤区CBV第90百分位治疗后升高或停滞提示生存较短,下降提示生存较长。
- 肿瘤区Ktrans-T2*治疗后变化与总生存相关,表现与CBV类似。
- 瘤周区灌注参数变化与总生存未见关系。
核心结论
- 肿瘤体积内最高CBV及Ktrans-T2*值的治疗后变化是高级别胶质瘤患者总生存的预测因素。
- 肿瘤区CBV第90百分位升高或停滞者生存较短,下降者生存较长(393 ± 189 天 vs 594 ± 294 天;log-rank p = 0.019;Cox风险比 2.31;95%CI 1.12–4.74)。
- Ktrans-T2*显示类似结果(414 ± 177 天 vs 553 ± 312 天;log-rank p = 0.037;风险比 2.19;95%CI 1.03–4.65)。
- 瘤周区参数值与总生存无关系。
研究设计与样本
- 研究纳入45例组织学确诊的高级别星形细胞瘤患者,其中8例III级、37例IV级。
- 所有患者均于治疗前后接受T2*加权对比增强MR灌注成像。
- 对肿瘤、瘤周及对照体积进行分割,计算CBF、CBV、MTT、Ktrans-T2*、kep-T2*、ve-T2*及vp-T2*的相对变化。
- 采用ANOVA检验评估肿瘤分级和手术切除范围方面的差异;每个参数通过非监督聚类分为两组,并对这些组进行生存分析。
关键影像表现/征象
- 肿瘤区CBV第90百分位治疗后升高或停滞与较短生存相关,下降与较长生存相关。
- 肿瘤区Ktrans-T2*治疗后变化与总生存相关,表现与CBV类似。
- 瘤周区灌注参数值治疗后变化与总生存未见关系。
诊断标准与关键数值
- 肿瘤区CBV第90百分位升高或停滞组生存393 ± 189天 vs 下降组594 ± 294天(log-rank p = 0.019;Cox风险比 2.31;95%CI 1.12–4.74)。
- 肿瘤区Ktrans-T2*升高或停滞组生存414 ± 177天 vs 下降组553 ± 312天(log-rank p = 0.037;风险比 2.19;95%CI 1.03–4.65)。
- 每个灌注参数通过非监督聚类分为两组进行生存分析。
临床应用与阅片要点
- 定量评估MRI灌注可提供有关肿瘤侵袭性的有价值信息。
- 定量T2*加权灌注参数有助于预测总生存。
- CBV和Ktrans-T2*值的治疗后变化是总生存的预测因素。
- 作者指出,数值升高可能为这些患者强化治疗提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Vascular characteristics of tumour and peritumoral volumes of high-grade gliomas change with treatment. This work evaluates the variations of T2*-weighted perfusion parameters as overall survival (OS) predictors.
METHODS: Forty-five patients with histologically confirmed high-grade astrocytoma (8 grade III and 37 grade IV) were included. All patients underwent pre- and post-treatment T2*-weighted contrast-enhanced magnetic resonance (MR) imaging. Tumour, peritumoral and control volumes were segmented. Relative variations of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), Ktrans-T2*, kep-T2*, ve-T2* and vp-T2* were calculated. Differences regarding tumour grade and surgical resection extension were evaluated with ANOVA tests. For each parameter, two groups were defined by non-supervised clusterisation. Survival analysis were performed on these groups.
RESULTS: For the tumour region, the 90th percentile increase or stagnation of CBV was associated with shorter survival, while a decrease related to longer survival (393 ± 189 vs 594 ± 294 days; log-rank p = 0.019; Cox hazard-ratio, 2.31; 95% confidence interval [CI], 1.12-4.74). Ktrans-T2* showed similar results (414 ± 177 vs 553 ± 312 days; log-rank p = 0.037; hazard-ratio, 2.19; 95% CI, 1.03-4.65). The peritumoral area values showed no relationship with OS.
CONCLUSIONS: Post-treatment variations of the highest CBV and Ktrans-T2* values in the tumour volume are predictive factors of OS in patients with high-grade gliomas.
KEY POINTS: • Vascular characteristics of high-grade glioma tumour and peritumoral regions change with treatment. • Quantitative assessment of MRI perfusion provides valuable information regarding tumour aggressiveness. • Quantitative T2*-weighted perfusion parameters can help to predict overall survival. • Post-treatment variations of CBV and K trans-T2 values are predictive factors of OS. • Increased values may justify treatment intensification in these patients.
引用
- Sanz-Requena R, Revert-Ventura AJ, García-Martí G, et al. Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma. Eur Radiol. 2016. PMID: 27999986. doi:10.1007/s00330-016-4699-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。